Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359028 | 0.79 | NPC1 (0.44) | CYP2A6TRPA1F12PLAUNCF1 | |
| SCHEMBL31023138 | 0.79 | CYP2A6 (0.47) | CYP2A6TRPA1F12PLAUNCF1 | |
| SCHEMBL28958132 | 0.79 | TRPA1 (0.47) | CYP2A6TRPA1F12PLAUNCF1 | |
| SCHEMBL30223171 | 0.79 | CYP2A6 (0.55) | CYP2A6TRPA1F12PLAUNCF1 | |
| SCHEMBL2231183 | 0.79 | CYP2A6 (0.55) | CYP2A6TRPA1F12PLAUNCF1 | |
| SCHEMBL10578906 | 0.78 | TRPA1 (0.43) | CYP2A6TRPA1F12PLAUNCF1 | |
| SCHEMBL31498832 | 0.78 | TRPA1 (0.60) | CYP2A6TRPA1F12PLAUNCF1 | |
| SCHEMBL6110247 | 0.78 | TRPA1 (0.60) | CYP2A6TRPA1F12PLAUNCF1 | |
| SCHEMBL13409343 | 0.77 | LRRK2 (0.42) | CYP2A6CYP1A2ALDH1A1LRRK2 | |
| SCHEMBL13409306 | 0.77 | LRRK2 (0.42) | TRPA1LMNACYP1A2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | claimed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-2427195-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9315505-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2014-10-02 | — | — | US | disclosed |
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2010129816-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-7705146-B2 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7696242-B2 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7605215-B2 | Process for producing olefin copolymerization catalyst and process for producing olefin copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20080227937-A1 | Process for Producing Olefin Copolymerization Catalyst and Process for Producing Olefin Copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | CYP2A6 1644/4885TRPA1 4837/4885F12 77/4885 |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | CYP2A6 1910/4885TRPA1 4856/4885F12 129/4885 |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | CYP2A6 3555/4885TRPA1 2268/4885F12 90/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | CYP2A6 3370/4885TRPA1 1974/4885F12 104/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | CYP2A6 3555/4885TRPA1 2268/4885F12 90/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | CYP2A6 3555/4885TRPA1 2268/4885F12 90/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | CYP2A6 3113/4885TRPA1 2409/4885F12 113/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | CYP2A6 1644/4885TRPA1 4837/4885F12 77/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | CYP2A6 3555/4885TRPA1 2268/4885F12 90/4885 |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | CYP2A6 1808/4885TRPA1 520/4885F12 2443/4885 |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, AKT3, PIK3CD | CYP2A6 2913/4885TRPA1 4374/4885F12 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.